Stem Cell Expansion via Minimal Manipulation and Cryopreservation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for expanding mesenchymal stem cells (MSCs) face limitations such as limited proliferative capacity, contamination with other cell types, cellular senescence, reduced differentiation potential, and tumorigenic potential due to extensive subcultivation and in vitro cultivation, which compromise the quality and yield of MSCs for therapeutic applications.
Innovation Solution
A method involving minimal manipulation of explant tissue, repeated harvesting cycles with mechanical transfer and culture in growth medium, allowing for semi-confluent stem cell collection and passaging, which maintains stem cell characteristics and increases cell numbers without enzymatic treatment, thereby reducing passages and maintaining karyotype stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If extensive in vitro cultivation and multiple cell passages are used to expand MSCs to therapeutically relevant numbers, then the yield of stem cells is improved, but the quality of cells deteriorates due to cellular senescence, reduced differentiation potential, and loss of growth factor production
Solution Approach 1:
The patent applies preliminary action by using allogeneic MSCs that have been pre-expanded and cryopreserved at low passages (below 5) when cells still possess high differentiation potential and growth factor production capacity. These pre-prepared cells are stored and ready for immediate therapeutic use, eliminating the need for extensive in vitro cultivation at the time of treatment and preventing cellular senescence and quality deterioration.
Solution Approach 2:
The patent creates a copy system by establishing a bank of cryopreserved allogeneic MSCs that replicate the therapeutic potential of freshly isolated cells. The cryopreserved cells serve as stable copies that can be stored indefinitely and used on demand, avoiding repeated passages that would compromise cell quality while maintaining consistent therapeutic efficacy across multiple treatments.
2Quantity of substance
If MSCs are expanded through multiple passages in culture, then the number of cells increases, but the differentiation capacity and growth factor production are reduced
Solution Approach 1:
The patent performs cell expansion and differentiation capacity preservation in advance by maintaining MSCs at low passages during cryopreservation. The cells are pre-expanded only to the extent necessary to create sufficient stock, then frozen at passage below 5 when differentiation markers and growth factor production are still optimal, preserving manufacturing precision for future therapeutic applications.
Solution Approach 2:
The patent utilizes the self-renewal capacity of MSCs during the initial expansion phase to generate sufficient cell numbers without requiring multiple passages. The cells serve themselves by naturally proliferating under optimized culture conditions, achieving the required quantity while maintaining differentiation potential through controlled, limited expansion rather than extensive passaging.
3Adaptability or versatility
If allogeneic MSCs are used for therapy, then the availability of cells is improved, but the risk of immune rejection and contamination with other cell types increases
Solution Approach 1:
The patent applies taking out by isolating and selecting only the desired MSC population from the allogeneic donor tissue through careful isolation protocols. This extraction process removes unwanted cell types (such as hematopoietic stem cells and other contaminants) that would otherwise be present in the whole bone marrow or tissue sample, achieving high purity MSC populations suitable for allogeneic therapy while minimizing immune rejection risks.
Solution Approach 2:
The patent utilizes parameter changes in the form of surface marker expression profiles to identify and select MSCs with low immunogenicity. By characterizing cells based on specific surface markers and selecting allogeneic donors with compatible HLA profiles, the patent modifies the immunological parameters of the cell population to reduce rejection risk while maintaining the allogeneic availability advantage.
4Object-affected harmful factors
If adult MSCs are used instead of embryonic stem cells, then the ethical concerns are reduced, but the proliferative capacity is limited
Solution Approach 1:
The patent applies preliminary action by harvesting and cryopreserving allogeneic MSCs at low passages when their proliferative capacity is still high. This advance preparation allows the cells to be stored in a state of high viability and expansion potential, enabling sufficient cell numbers to be obtained for therapy without requiring extensive in vitro cultivation that would exhaust the limited proliferative capacity of adult MSCs.
Solution Approach 2:
The patent maintains continuity of useful action by using cryopreserved cells that retain their original in vivo characteristics and proliferative potential. The cells are stored in a state that preserves their biological activity and can be thawed and expanded when needed, ensuring continuous availability of high-quality cells without the need to repeatedly passage cells through culture, which would gradually reduce their proliferative capacity.
Data Source
Figure 1A~2
Figure 3
Figure 4~5
AI summary
The present method relates to methods of expanding or increasing stem cell production obtained from donor samples. The methods preferably including the steps of harvesting cells from minimally manipulated tissue using multiply harvesting cycles to increase the number of obtained stem cells.